On Tuesday, Ocular Therapeutix Inc (NASDAQ: OCUL) was 3.58% up from the session before settling in for the closing price of $7.55. A 52-week range for OCUL has been $4.06 – $11.77.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 123.40%. When this article was written, the company’s average yearly earnings per share was at -16.86%. With a float of $135.64 million, this company’s outstanding shares have now reached $156.65 million.
The extent of productivity of a business whose workforce counts for 267 workers is very important to gauge. In terms of profitability, gross margin is 90.58%, operating margin of -230.12%, and the pretax margin is -284.02%.
Ocular Therapeutix Inc (OCUL) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Ocular Therapeutix Inc stocks. The insider ownership of Ocular Therapeutix Inc is 13.72%, while institutional ownership is 75.92%. The most recent insider transaction that took place on Feb 04 ’25, was worth 86,839. In this transaction an insider of this company sold 11,119 shares at a rate of $7.81, taking the stock ownership to the 193,444 shares. Before that another transaction happened on Jan 31 ’25, when Company’s insider sold 6,301 for $7.84, making the entire transaction worth $49,400. This insider now owns 204,563 shares in total.
Ocular Therapeutix Inc (OCUL) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -16.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.54% during the next five years compared to 8.38% growth over the previous five years of trading.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
You can see what Ocular Therapeutix Inc (OCUL) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 12.94. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 20.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.32, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -1.07 in one year’s time.
Technical Analysis of Ocular Therapeutix Inc (OCUL)
The latest stats from [Ocular Therapeutix Inc, OCUL] show that its last 5-days average volume of 1.08 million was superior to 0.9 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 28.37%. Additionally, its Average True Range was 0.38.
During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 8.55%, which indicates a significant decrease from 39.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 24.98% in the past 14 days, which was lower than the 51.45% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.64, while its 200-day Moving Average is $8.07. Now, the first resistance to watch is $7.97. This is followed by the second major resistance level at $8.11. The third major resistance level sits at $8.34. If the price goes on to break the first support level at $7.60, it is likely to go to the next support level at $7.37. The third support level lies at $7.23 if the price breaches the second support level.
Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats
There are 157,217K outstanding shares of the company, which has a market capitalization of 1.23 billion. As of now, sales total 58,440 K while income totals -80,740 K. Its latest quarter income was 15,430 K while its last quarter net income were -36,490 K.
